DUBLIN – Funding for European biopharmaceutical companies is down 43 percent for the first three quarters of 2016 compared with the same period last year, with total equity investment dropping to $2.335 million from $4.119 million. Read More
Continuing a flurry of dealmaking that has spanned both the generic and branded drug markets, Teva Pharmaceutical Industries Ltd. inked its latest deal, a North American alliance with Korean firm Celltrion Inc. aimed at expanding its role in the growing biosimilars space. Read More
Fewer prescription opioids will be on the U.S. market next year, thanks to sharp reductions in the annual quotas set this week by the Drug Enforcement Administration (DEA) as part of its war on opioid abuse. Read More
LONDON – DNA Electronics Ltd. has been awarded up to $51.9 million under President Barack Obama's Action Plan for Combatting Antibiotic Resistant Bacteria, to develop a point-of-care next-generation DNA sequencing device for identifying the cause of infections. Read More
Concordia International Corp., of Oakville, Ontario, said it intends to start an offering of up to $350 million of new 5.5-year senior secured first lien notes. The net proceeds will be used to strengthen the company's liquidity position and augment its product development pipeline beyond the anticipated, and previously disclosed, 60 product launches expected by the fourth quarter of 2018. Read More
AUM Lifetech Inc., of Philadelphia, said it is developing a new approach to HIV treatment, in collaboration with the Beckman Research Institute at the City of Hope in California, and McGill University in Montreal. Read More
Vaccinex Inc., of Rochester, N.Y., said it will work with Darmstadt, Germany-based Merck KGaA to evaluate VX15/2503, an investigational humanized anti-semaphorin 4D antibody, in combination with avelumab, an investigational anti-PD-L1 antibody, in patients with advanced non-small-cell lung cancer who have not previously received immunotherapy. Read More
